Skip to main content

Advertisement

SpringerLink
Log in

Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation

  • Rapid Communication
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Busulfan (Bu), an alkylating agent, has been used in pre-transplant conditioning regimens since the 1950s, due to its potent myeloablative effect. Questions have been raised regarding oral or intravenous formulations, although both are known to be associated with serious side effects, including hepatic veno-occlusive disease, and neurotoxicity. The administration of anticonvulsant prophylaxis has become more common during high-dose Bu-based conditioning regimen; however, anticonvulsants can interfere with Bu pharmacokinetics and may have their own side effects, which can affect the outcome of the transplant. Our objective was to analyze the incidence of neurotoxicity in patients who underwent stem cell transplantation with high-dose Bu-based conditioning regimens without anticonvulsant prophylaxis. Ninety-seven patients were included, either having received a dose of 12 mg/kg (n = 73) for allogeneic transplantation or 16 mg/kg (n = 24) for autologous transplantation. The incidence of seizures was 0.01 %. We conclude that anticonvulsant prophylactic regimens may be unnecessary, and reduction of their use may help to avoid potential drug interactions and undesired side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Haddow A, Timmis GM. Myleran in chronic myeloid leukemia. Chemical constitution and biological action. Lancet. 1953;264(6753):207–8.

    Article  CAS  PubMed  Google Scholar 

  2. Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(5):523–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Santos GW, Tutschka PJ. Marrow transplantation in the busulfan-treated rat: preclinical model of aplastic anemia. J Natl Cancer Inst. 1974;53:1781–5.

    CAS  PubMed  Google Scholar 

  4. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309:1347–53.

    Article  CAS  PubMed  Google Scholar 

  5. Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Flournoy N. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977;49(4):511–33.

    CAS  PubMed  Google Scholar 

  6. Bleyer AW, Blaese RM, Bujak JS, Herzig GP, Graw RG. Long-term remission from acute myelogenous leukemia after bone marrow transplantation and recovery from acute graft-versus-host reaction and prolonged immunoincompetence. Blood. 1975;45:171–81.

    CAS  PubMed  Google Scholar 

  7. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987;70(5):1382–8.

    CAS  PubMed  Google Scholar 

  8. Copelan EA, Biggs JC, Thompson JM, Crilley P, Szer J, Klein JP. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood. 1991;78(3):838–43.

    CAS  PubMed  Google Scholar 

  9. Krivoy N, Hoffer E, Lurie Y, Bentur Y, Rowe JM. Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children. Curr Drug Saf. 2008;3(1):60–6.

    Article  CAS  PubMed  Google Scholar 

  10. Santos GW. Busulfan (Bu) and cyclophosphamide (Cy) for marrow transplantation. Bone Marrow Transplant. 1989;4(Suppl 1):236–9.

    PubMed  Google Scholar 

  11. Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplant conditioning therapy: a phase I study. Biol Blood Marrow Transplant. 2000;6(5A):548–54.

    Article  CAS  PubMed  Google Scholar 

  12. Bhagwatwar HP, Phadungpojna S, Chow DS, Andersson BS. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol. 1996;37(5):401–40.

    Article  CAS  PubMed  Google Scholar 

  13. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood. 1995;85(11):3005–20.

    CAS  PubMed  Google Scholar 

  14. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol. 1993;20(4 Suppl 4):18–25 (quiz 26).

  15. Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 1990;50(19):6203–7.

    CAS  PubMed  Google Scholar 

  16. Marcus RE, Goldman JM. Convulsions due to high-dose busulphan. Lancet. 1984;2(8417–8418):1463.

    Article  CAS  PubMed  Google Scholar 

  17. Vassal G, Gouyette A, Hartmann O, Pico JL, Lemerle J. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol. 1989;24(6):386–90.

    Article  CAS  PubMed  Google Scholar 

  18. Hassan M, Oberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol. 1989;36(5):525–30.

    Article  CAS  PubMed  Google Scholar 

  19. Eberly AL, Anderson GD, Bubalo JS, McCune JS. Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy. 2008;28(12):1502–10.

    Article  CAS  PubMed  Google Scholar 

  20. Chan KW, Mullen CA, Worth LL, Choroszy M, Koontz S, Tran H. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant. 2002;29(12):963–5.

    Article  CAS  PubMed  Google Scholar 

  21. Floeter AE, McCune JS. Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. J Oncol Pharm Pract. 2016 (Epub ahead of print).

  22. Diaz-Carrasco MS, Olmos R, Blanquer M, Velasco J, Sánchez-Salinas A, Moraleda JM. Clonazepam for seizure prophylaxis in adult /patients treated with high dose busulfan. Int J Clin Pharm. 2013;35(3):339–43.

    Article  CAS  PubMed  Google Scholar 

  23. Carreras E, Cahn JY, Puozzo C, Kröger N, Sanz G, Buzyn A. Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data. Anticancer Res. 2010;30(7):2977–84.

    CAS  PubMed  Google Scholar 

  24. Hassan M, Oberg G, Björkholm M, Wallin I, Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol. 1993;33(3):181–6.

    Article  CAS  PubMed  Google Scholar 

  25. Meloni G, Raucci U, Pinto RM, Spalice A, Vignetti M, Iannetti P. Pretrasplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: neurological and electroencephalographic prospective study. Ann Oncol. 1992;3(2):145–8.

    CAS  PubMed  Google Scholar 

  26. Murphy CP, Harden EA, Thompson JM. Generalized seizures secondary to high-dose busulfan therapy. Ann Pharmacother. 1992;26(1):30–1.

    CAS  PubMed  Google Scholar 

  27. Hartmann O, Benhamou E, Beaujean F, Pico JL, Kalifa C, Patte C. High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase II study. J Clin Oncol. 1986;4(12):1804–10.

    CAS  PubMed  Google Scholar 

  28. Kobayashi R, Watanabe N, Iguchi A, Cho Y, Yoshida M, Arioka H. Electroencephalogram abnormality and high-dose busulfan in conditioning regimens for stem cell transplantation. Bone Marrow Transplant. 1998;21(3):217–20.

    Article  CAS  PubMed  Google Scholar 

  29. La Morgia C, Mondini S, Guarino M, Bonifazi F, Cirignotta F. Busulfan neurotoxicity and EEG abnormalities: a case report. Neurol Sci. 2004;25(2):95–7.

    Article  PubMed  Google Scholar 

  30. De La Camara R, Tomas JF, Figuera A, Berberana M, Fernandez-Rañada JM. High dose busulfan and seizures. Bone Marrow Transplant. 1991;7(5):363–4.

    Google Scholar 

  31. Caselli D, Rosati A, Faraci M, Podda M, Ripaldi M, Longoni D. Risk of seizures in children receiving busulphan-containing regimens for stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(2):282–5.

    Article  CAS  PubMed  Google Scholar 

  32. Ruiz-Argüelles GJ, Gomez-Almaguer D, Steensma DP. Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting. Am J Hematol. 2012;87(9):941.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stem Cell Transplantation Program, Hematology and Oncology Department, Instituto Nacional de Ciencias Medicas Y Nutricion Salvador Zubiran, Vasco de Quiroga 15, Belisario Dominguez Seccion XVI, Tlalpan, 14080, Mexico City, Mexico

    Eucario Leon-Rodriguez & Monica M. Rivera-Franco

Authors
  1. Eucario Leon-Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monica M. Rivera-Franco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eucario Leon-Rodriguez.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interests.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leon-Rodriguez, E., Rivera-Franco, M.M. Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation. Int J Hematol 104, 644–646 (2016). https://doi.org/10.1007/s12185-016-2098-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-016-2098-8

Keywords

Search

Navigation